2154-24-7

Usage

Uses

Used in Pharmaceutical Industry:
(2-Morpholin-4-yl-ethyl)-hydrazine is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure, featuring a morpholine ring and an ethyl group, allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, (2-Morpholin-4-yl-ethyl)-hydrazine is utilized as a building block for the creation of novel agrochemicals. Its ability to form stable derivatives makes it a valuable component in the design of new pesticides, herbicides, and other agricultural chemicals aimed at enhancing crop protection and yield.
Used in Chemical Synthesis:
(2-Morpholin-4-yl-ethyl)-hydrazine serves as a versatile chemical intermediate in the synthesis of various organic compounds. Its reactivity and functional groups enable the formation of a wide range of derivatives, making it a valuable asset in the development of new chemical entities for diverse applications.
Used in Biological Activity Research:
(2-Morpholin-4-yl-ethyl)-hydrazine is employed in research studies to investigate its potential biological activity. Its unique structure and functional groups make it an interesting candidate for exploring its effects on biological systems, which could lead to the discovery of new therapeutic agents or insights into biological processes.
Used in Toxicological Studies:
In toxicological research, (2-Morpholin-4-yl-ethyl)-hydrazine is used to evaluate its potential toxic effects on living organisms. Understanding its toxicological properties is crucial for assessing its safety and determining its suitability for use in various applications, including pharmaceuticals and agrochemicals.

Upstream product

• 3647-69-6 4-(2-chloroethyl)morpholine hydrochride 
• 89583-07-3 N-(2-bromoethyl)morpholine 
• 3240-94-6 N-(2-chlorethyl)morpholine 

Downstream Products

• 33048-50-9 2-(2-morpholin-4-yl-ethyl)-4-phenyl-2H-phthalazin-1-one 
• 49869-19-4 2-(2-morpholin-4-yl-ethyl)-8-phenyl-4,5,6,7-tetrahydro-2H-[1,2]diazocin-3-one 
• 29242-45-3 6-(4-bromo-phenyl)-4-methyl-2-(2-morpholin-4-yl-ethyl)-2H-pyridazin-3-one 
• 29242-44-2 6-(3-bromo-phenyl)-4-methyl-2-(2-morpholin-4-yl-ethyl)-2H-pyridazin-3-one 
• 29285-75-4 6-(2-hydroxy-phenyl)-4-methyl-2-(2-morpholin-4-yl-ethyl)-2H-pyridazin-3-one 
• 22139-58-8 3-(3,4-dihydroxy-phenyl)-acrylic acid N'-(2-morpholin-4-yl-ethyl)-hydrazide 
• 21769-53-9 3-(2-morpholin-4-yl-ethyl)-5-phenyl-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one 
• 51313-42-9 6-(2-morpholin-4-yl-ethyl)-4-phenyl-6H-isoxazolo[3,4-d]pyridazin-7-one 
• 1099657-54-1 C₁₉H₂₅ClN₆O₂ 
• 51244-57-6 3-methyl-6-(2-morpholin-4-yl-ethyl)-4-phenyl-6H-isoxazolo[3,4-d]pyridazin-7-one 

Relevant academic research and scientific papers

2-Pyrazolin-5-ones bearing a basic dialkylaminoalkyl substituent at the N1-position: Preparation and NMR spectroscopic investigations

2-Pyrazolin-5-ones (= tautomers to 5-hydroxypyrazols) bearing dialkylaminoyalkyl substituents at the ring nitrogen atom N-1 are prepared from the corresponding hydrazines and beta-ketoesters. Detailed NMR spectroscopic investigations (1H,

Synthesis of 9,10-anthraquinone monoalkylaminoalkylhydrazones as potential antitumor drugs

In the constant search for new compounds endowed with antitumor activity we have synthesized a series of anthraquinone hydrazones, which can be seen either as opened-cycle modified anthrapyrazoles or as chromophore-modified anthracenediones. Seven 9,10-anthraquinone monoalkylaminoalkylhydrazones (3c-i) were synthesized from 10,10-dibromoanthrone (4) and a suitable N-alkylhydrazine. The hydrazones were converted into hydrochlorides and tested for their cytotoxic activity against L1210 murine leukemia cells. Two of them possess marginal activity in vitro.

3-[1-(2-Benzoxazolyl)hydrazino]propanenitrile derivatives: Inhibitors of immune complex induced inflammation

3-[1-(2-Benzoxazolyl)hydrazino]propanenitrile derivatives were evaluated in the dermal and pleural reverse passive Arthus reactions in the rat. In the pleural test these compounds were effective in reducing exudate volume and accumulation of white blood cells. This pattern of activity was similar to that of hydrocortisone and different from that of indomethacin. The structural requirements for inhibiting the Arthus reactions were studied by systematic chemical modification of 1. These structure-activity relationship studies revealed that nitrogen 1' of the hydrazino group is essential for activity and must be electron rich, whereas chemical modifications of other sites of 1 had only a modest effect on activity.